Palvella lands third FDA grant year for QTORIN rapamycin after Phase 3 win
What's the deal? Palvella Therapeutics has received a third year of grant funding from the FDA Office of Orphan Products Development for its Phase 3 SELVA trial and open-label extension study of QTORIN 3.9% rapamycin gel. The topical therapy targets microcystic lymphatic malformations, a rare vascular anomaly affecting an estimated 30,000-plus pediatric and adult patients in the US.
Why now? The grant follows the FDA's review of Palvella's annual progress report, which included SELVA trial results. The trial met its primary endpoint, key secondary endpoint, and all four secondary efficacy endpoints, with all six achieving statistical significance (p<0.001).
What's the endgame? Palvella completed its New Drug Application for QTORIN rapamycin in August 2026. It is now advancing commercial readiness for a potential US launch in the first half of 2027, pending regulatory approval.
The context: SELVA was one of seven trials selected from 51 applications by the FDA Orphan Products Grants Program in fiscal year 2024 — and the only Phase 3 trial funded that year. Palvella is also studying QTORIN rapamycin for cutaneous venous malformations and angiokeratomas, plus a separate candidate, QTORIN pitavastatin, for a skin condition.
What could go wrong? Both QTORIN candidates remain investigational and have not been approved by the FDA or any other regulator. PVLA shares closed at $138.16 on Monday, down 5.42%, within a 52-week range of $59.16 to $161.38.
The signal: Repeat federal backing for a single Phase 3 program is uncommon and signals regulatory confidence in a rare-disease candidate that has cleared its pivotal trial and reached the NDA stage.
Read more: rttnews.com
Image credit: NavyMedicine
